UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients

PloS one, 2009-09, Vol.4 (9), p.e7125-e7125

2009

Volltextzugriff (PDF)

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate

Cardiovascular diabetology, 2017-01, Vol.16 (1), p.6-6, Article 6

2017

Volltextzugriff (PDF)

Benefits of a Switch from Intermittently Scanned Continuous Glucose Monitoring (isCGM) to Real-Time (rt) CGM in Diabetes Type 1 Suboptimal Controlled Patients in Real-Life: A One-Year Prospective Study

Sensors (Basel, Switzerland), 2021-09, Vol.21 (18), p.6131

2021

Volltextzugriff (PDF)

Health and Pleasure in Consumers' Dietary Food Choices: Individual Differences in the Brain's Value System

PloS one, 2016-07, Vol.11 (7), p.e0156333-e0156333

2016

Volltextzugriff (PDF)

Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues

Expert opinion on drug safety, 2017-02, Vol.16 (2), p.227-236

Raccah, Denis

2017

Volltextzugriff (PDF)

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin

Diabetes care, 2013-10, Vol.36 (10), p.2945-2951

2013

Volltextzugriff (PDF)

Clinical implications of prolonged hyperglycaemia before basal insulin initiation in type 2 diabetes patients: An electronic medical record database analysis

Endocrinology, diabetes & metabolism, 2019-07, Vol.2 (3), p.e00061-n/a

2019

Volltextzugriff (PDF)

Neuroprotective Effect of Docosahexaenoic Acid-Enriched Phospholipids in Experimental Diabetic Neuropathy

Diabetes (New York, N.Y.), 2003-10, Vol.52 (10), p.2578-2585

2003

Volltextzugriff (PDF)

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy

Diabetes care, 2012-06, Vol.35 (6), p.1225-1231

2012

Volltextzugriff (PDF)

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

Diabetes care, 2012-06, Vol.35 (6), p.1225-1231

2012

Volltextzugriff (PDF)

Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data

Expert review of endocrinology & metabolism, 2013-03, Vol.8 (2), p.105-121

Raccah, Denis

2013

Volltextzugriff (PDF)

Incremental Value of Continuous Glucose Monitoring When Starting Pump Therapy in Patients With Poorly Controlled Type 1 Diabetes: The RealTrend study

Diabetes care, 2009-12, Vol.32 (12), p.2245-2250

2009

Volltextzugriff (PDF)

Lixisenatide once daily significantly improves post-prandial glucose throughout the day due to diverse mechanistic effects

Expert review of endocrinology & metabolism, 2014-05, Vol.9 (3), p.201-203

Raccah, Denis

2014

Volltextzugriff (PDF)

Impact of Switching from Intermittently Scanned to Real-Time Continuous Glucose Monitoring Systems in a Type 1 Diabetes Patient French Cohort: An Observational Study of Clinical Practices

Diabetes technology & therapeutics, 2021-04, Vol.23 (4), p.259-267

2021

Volltextzugriff (PDF)

Incremental Value of Continuous Glucose Monitoring When Starting Pump Therapy in Patients With Poorly Controlled Type 1 Diabetes

Diabetes care, 2009-12, Vol.32 (12), p.2245-2250

2009

Volltextzugriff (PDF)

Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus

Expert opinion on drug metabolism & toxicology, 2017-03, Vol.13 (3), p.311-321

2017

Volltextzugriff (PDF)

Reply to Letter by Alexander Seibold on “Impact of Switching from Intermittently Scanned to Real-Time Continuous Glucose Monitoring Systems in a Type 1 Diabetes Patient French Cohort: An Observational Study of Clinical Practices” by Yannis Préau, et al. (doi: 10.1089/dia.2020.0674)

Diabetes technology & therapeutics, 2021-08, Vol.23 (8), p.598-600

2021

Volltextzugriff (PDF)

Efficacy and safety of lixisenatide in elderly ( ≥65 years old) and very elderly ( ≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme

Diabetes/metabolism research and reviews, 2015-02, Vol.31 (2), p.204-211

2015

Volltextzugriff (PDF)

Impact of Type 2 Diabetes (T2D) Duration on Response to iGlarLixi vs. IGlar—A Subanalysis of LixiLan-L

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Volltextzugriff (PDF)

Real‐time continuous glucose monitoring in type 1 diabetes: a systematic review and individual patient data meta‐analysis

Clinical endocrinology (Oxford), 2017-03, Vol.86 (3), p.354-360

2017

Volltextzugriff (PDF)

A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin

Diabetes/metabolism research and reviews, 2017-03, Vol.33 (3), p.np-n/a

2017

Volltextzugriff (PDF)

Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes

Diabetes/metabolism research and reviews, 2014-11, Vol.30 (8), p.742-748

2014

Volltextzugriff (PDF)

When basal insulin therapy in type 2 diabetes mellitus is not enough-what next?

Diabetes/metabolism research and reviews, 2007-05, Vol.23 (4), p.257-264

2007

Volltextzugriff (PDF)

TT Virus Infection in French Hemodialysis Patients: Study of Prevalence and Risk Factors

Journal of Clinical Microbiology, 1999-08, Vol.37 (8), p.2538-2542

1999

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(68)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(38)
Humans
(31)
Endocrinology & Metabolism
(24)
Male
(23)
Adult
(19)
Diabetes
(17)
Biological And Medical Sciences
(16)
Female
(16)
Medical Sciences
(15)
Middle Aged
(15)
Diabetes. Impaired Glucose Tolerance
(13)
Endocrine Pancreas. Apud Cells
(13)
Endocrinopathies
(13)
Hypoglycemic Agents - Therapeutic Use
(12)
Insulin
(11)
Life Sciences
(11)
Aged
(10)
Diabetes Mellitus, Type 2 - Drug Therapy
(10)
Type 2 Diabetes
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate

Benefits of a Switch from Intermittently Scanned Continuous Glucose Monitoring (isCGM) to Real-Time (rt) CGM in Diabetes Type 1 Suboptimal Controlled Patients in Real-Life: A One-Year Prospective Study

Health and Pleasure in Consumers' Dietary Food Choices: Individual Differences in the Brain's Value System

Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial

Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin

Clinical implications of prolonged hyperglycaemia before basal insulin initiation in type 2 diabetes patients: An electronic medical record database analysis

Neuroprotective Effect of Docosahexaenoic Acid-Enriched Phospholipids in Experimental Diabetic Neuropathy

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data

Incremental Value of Continuous Glucose Monitoring When Starting Pump Therapy in Patients With Poorly Controlled Type 1 Diabetes: The RealTrend study

Lixisenatide once daily significantly improves post-prandial glucose throughout the day due to diverse mechanistic effects

Impact of Switching from Intermittently Scanned to Real-Time Continuous Glucose Monitoring Systems in a Type 1 Diabetes Patient French Cohort: An Observational Study of Clinical Practices

Incremental Value of Continuous Glucose Monitoring When Starting Pump Therapy in Patients With Poorly Controlled Type 1 Diabetes

Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus

Reply to Letter by Alexander Seibold on “Impact of Switching from Intermittently Scanned to Real-Time Continuous Glucose Monitoring Systems in a Type 1 Diabetes Patient French Cohort: An Observational Study of Clinical Practices” by Yannis Préau, et al. (doi: 10.1089/dia.2020.0674)

Efficacy and safety of lixisenatide in elderly ( ≥65 years old) and very elderly ( ≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme

Impact of Type 2 Diabetes (T2D) Duration on Response to iGlarLixi vs. IGlar—A Subanalysis of LixiLan-L

Real‐time continuous glucose monitoring in type 1 diabetes: a systematic review and individual patient data meta‐analysis

A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin

Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes

When basal insulin therapy in type 2 diabetes mellitus is not enough-what next?

TT Virus Infection in French Hemodialysis Patients: Study of Prevalence and Risk Factors

Suchergebnisse filtern